CN1296847A - Medicinal composition for treating asthma and tracheitis - Google Patents
Medicinal composition for treating asthma and tracheitis Download PDFInfo
- Publication number
- CN1296847A CN1296847A CN 99123941 CN99123941A CN1296847A CN 1296847 A CN1296847 A CN 1296847A CN 99123941 CN99123941 CN 99123941 CN 99123941 A CN99123941 A CN 99123941A CN 1296847 A CN1296847 A CN 1296847A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- treatment
- portions
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A composite Chinese medicine in the form tablet, pill, capsule, oral liquid, syrup, or instant particles for treating asthma and tracheitis is prepared from 12 Chinese-medicinal materials including ephedra, cinammon twigs, almond, liquorice root, etc. wetting agent, antiseptic, disintegrant, lubricant, diluent, or excipient.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of asthma, tracheitis, specifically the present invention relates to a kind of pharmaceutical composition of forming by Chinese medicine Herba Ephedrae, Ramulus Cinnamomi, Semen Armeniacae Amarum, Radix Glycyrrhizae, Bulbus Fritillariae Uninbracteatae, Radix Ginseng, Fu Ling, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Fructus Psoraleae, Gecko, Cordyceps.
Bronchial asthma is a kind of in the respiratory tract disease and since the pathogeny of this disease as yet a surname do not illustrate entirely, make Chinese and western medicine in treatment, very big limitation be arranged.The traditional Chinese medical science generally adopts the drink that reduces phlegm, cough-relieving is breathed heavily and the method for strengthening spleen, tonifying kidney, adopt ERCHEN TANG, XIAOQINGLONG TANG, JINGUI SHENQI WAN etc., but curative effect is of short duration more, low and easy recurrence of cure rate; Doctor trained in Western medicine only at sensitinogen, anaphylaxis is abnormal and the clinical symptoms that showed, adopts antiinflammatory, antiallergic to conciliate the method that disease is relievingd asthma, and uses aminophylline, beta receptor analeptic, cholinolytic class, hormones and medium to discharge medicines such as retardance class; Can only the respite symptom, owing to can not effect a radical cure, make the patient have to take for a long time, thereby cause side effect such as hormone dependence, obesity, endocrine regulation.The inventor finds through long term studies, and existing these medicines have all been ignored and the inflammatory that causes is dyed because of dislike in the respiratory tract part burst and swing the repairing and treating of focus; The treatment of the disturbance of blood circulation that respiratory tract local inflammation (inflammatory damage capillary network, lung tissue swelling compressing blood capillary, blood be sticking, coagulate, aggregation increases etc.) is caused; Cause interstitial pulmonary fibrosis to cause gas-exchange membrane to thicken and the treatment of gas dispersion merit obstacle and respiratory tract local patholoic change (airway obstruction, gas are more bad, histoorgan anoxia and function reduction) cause allomeric function to go down to respiratory repeated infection, thereby body function go down and influence not only the repairing and treating of respiratory tract local patholoic change never effectively these diseases of treatment but also the less medicine of side effect really clinically conversely.
The present invention just provides a kind ofly like this to have YIN nourishing training unit, stablizes bronchial asthma patient machine
Internal milieu, strengthen adjusting of bronchial asthma patient organism adaptation and resistance against diseases, the effect of change air flue hypersensitive state is the less Chinese medicine composition of side effect again, is used for the treatment of bronchial asthma.
Chinese medicine composition of the present invention mainly comprises the active component that the Chinese crude drug by following proportioning makes: (by weight)
Herba Ephedrae 4--8 part, Ramulus Cinnamomi 7--11 part, Semen Armeniacae Amarum 9--15 part, Radix Glycyrrhizae 4-8 part, Bulbus Fritillariae Uninbracteatae 4--8 part, Radix Ginseng 7-11 part, Fu Ling 12--18 part, Rhizoma Atractylodis Macrocephalae 8--15 part, Fructus Schisandrae Chinensis 9--15 part, Fructus Psoraleae 9--15 part, Gecko 4--8 part, Cordyceps 4--8 part.
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Herba Ephedrae 5--7 part, Ramulus Cinnamomi 8--10 part, Semen Armeniacae Amarum 10.5--14 part, Radix Glycyrrhizae 5--7 part, Bulbus Fritillariae Uninbracteatae 5--7 part, Radix Ginseng 8-10 part, Fu Ling 13.5--16.5 part, Rhizoma Atractylodis Macrocephalae 10.5--13.5 part, Fructus Schisandrae Chinensis 10--13 part, Fructus Psoraleae 11.5--13.5 part, Gecko 5--7 part, Cordyceps 5--7 part.
Medicine optimum weight proportioning of the present invention is:
6 parts in Herba Ephedrae, 9 parts of Ramulus Cinnamomi, 12 parts in Semen Armeniacae Amarum, 6 parts in Radix Glycyrrhizae, 6 parts of Bulbus Fritillariae Uninbracteataes, 9 parts of Radix Ginsengs, 15 parts of Fu Ling, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Fructus Schisandrae Chinensis, 12 parts of Fructus Psoraleaes, 6 parts of Geckos, 6 parts of Cordycepss.
Active component in pharmaceutical composition of the present invention can be that acetone, chloroform, the second of said ratio Chinese crude drug is dim, the extract of ethyl acetate, alcohol or water, be preferably the extract of water or alcohol, more preferably ethanol extraction, wherein concentration of ethanol is 50-99%, preferred 95% ethanol.The percolation that extracting method is carried for conventional Chinese crude drug extracting method warm macerating as usual, reflux extraction etc. have thin description in the 65-72 page or leaf in Cao Chunlin chief editor " pharmaceutics of Chinese drugs ".
When the active component of preparation in the pharmaceutical composition of the present invention, when extracting solvent and be water, generally adopt decocting method to extract twice, each consumption all be 3-30 a times of Chinese crude drug, and preferred 25 times, extraction time is 1-5 hour for the first time, be 02-5 hour for the second time, merge decocting liquid twice, concentrate.When extracting solvent is pure elbow, generally adopts reflux extraction to extract once, and solvent load is 10-40 a times of Chinese crude drug weight, extraction time is 2-6 hour, extracting temperature is 50--80 ℃, reclaims solvent, and this extracting solution is condensed into the thick paste that relative density is 1-15 (50 ℃ of heat is surveyed).
The present composition can also comprise pharmaceutically acceptable additives such as wetting agent, antiseptic, disintegrating agent, lubricant, diluent or excipient etc., adopts the conventional method of this area can make various dosage forms such as tablet, pill, capsule, oral liquid, syrup, electuary etc.
The present composition has enriching yin boost qi and consolidates the effect of Dingchuan, can stablize bronchial asthma patient organismic internal environment, strengthen bronchial asthma patient organism adaptation and regulate and resistance against diseases, thereby change the purpose that the air flue hypersensitive state reaches treatment bronchial asthma.Clinically, medicine of the present invention consolidates medicine for the treatment chronic obstructive disease of lung, with treatment chronic obstructive disease of lung wound palliative with face the control medicine and unite use, and the clinical observation through 18 years, effective percentage and cure rate all are significantly increased, for bronchus, asthma patient have brought Gospel.And capsule of the present invention, have volume little, take and store that convenient transportation, produce effects are fast, the curative effect advantages of higher, having overcome oral liquid formulations must clarify, and makes that effective ingredient is lost in a large number, herb resource waste, production cost improve the also affected shortcoming of curative effect.
For showing that medicine of the present invention to the treatment of asthma effect, now provides following clinical data:
One, single with medicine of the present invention (dosage form is a capsule) treatment bronchial asthma:
(1), clinical data:
1. physical data: this group patient is a nineteen ninety-five December～be in hospital in July, the 1999 or patient of the non-status asthmaticus of out-patient treatment, male 65 examples in 116 examples, women 51 examples; Slight outbreak 26 examples, moderate 51 examples of showing effect, severe 39 examples of showing effect; Minimum 16 years old of age, maximum 70 years old; 54 years old mean age; Family history person's 35 examples are arranged, account for 31.0% of sum; Allergies person's 76 examples are arranged, account for 65.5% of sum; Chinese medical discrimination asthma of cold-type 39 examples, asthma of heat type 77 examples.
2. diagnostic criteria: this group patient meets the diagnostic criteria that the bronchial asthma of branch's formulation is breathed by Chinese Medical Association in 1993.The Chinese medical discrimination typing is with reference to the standard of nineteen eighty-three All-China Association of Traditional Chinese Medicine's internal medicine branch.
(2), Therapeutic Method
Medicament capsule of the present invention, an oral 2-3 grain, 3 times on the one, taking medicine after meal, 14 days courses of treatment
(3), observation of curative effect
Observation index: respectively at observe patient's cough, expectoration after the medication, pant, the variation of wheezing sound, tongue fur, pulse condition, measure the improvement situation of pulmonary function VC, FEV1.0/FVC, PEER.The disconnected standard of light, the middle major punishment of the clinical manifestation state of an illness is from intending.Cough: the cough on daytime does not influence orthobiosis and work (+); Cough round the clock influences orthobiosis, work and sleep (+++); (++) falls between.Expectoration 10～50ml (+); 51～100ml (++); The above person of 100ml (+++).Pant: accidental, do not influence sleep (+); Can not put down for sleeping inly, influence activity (+++); Between the two (++).Wheezing sound: two lung wheezing sounds idol is heard and (+); Two lung wheezing sounds are dispersed in fixing (++); Two lung wheezing sounds are abound with (+++).
(4), result
1. to the curative effect of symptom, sign
The comparison (example) that clinical symptoms, sign change before and after table 1 treatment
| Before the treatment | After the treatment | |||||
| ????+ | ????++ | ????+++ | ????+ | ????++ | ????+++ | |
| The cough and expectoration wheezing sound of panting | ????17 ????53 ????4 ????6 | ????46 ????41 ????78 ????67 | ????53 ????22 ????35 ????43 | ????47 ????59 ????74 ????72 | ????59 ????50 ????40 ????39 | ????10 ????7 ????2 ????5 |
Can see that from table 1 this pharmaceutical composition improves significantly to clinical symptoms, the sign of asthma.
2. the variation of pulmonary function before and after the treatment
The comparison of pulmonary function before and after table 2 treatment (X ± SD)
| ????VC(ml) | ???FEV1.0(ml) | ???FEV1.0/FVC | ???PEER(L/S) | |
| Before the treatment | 1506.9±776.8 | ?693.1±430.8??? | ?45.72±18.60??? | ?1.474±0.837 |
| After the treatment | 1808.8±746.6??? | ?1211.2±539.9 | ?58.91±22.02??? | ?1.886±1.091 |
| The P value | ????＜0.05 | ????＜0.01 | ????＜0.01 | ????＜0.05 |
Can find out that from table 2 treatment back VC, FEV1.0, FEV1.0/FVC, PEER all apparently higher than treatment preceding (P＜0.05 or P＜0.01), point out this pharmaceutical composition can improve pulmonary ventilation, improve pulmonary function.
Two, adopt medicine of the present invention (dosage form is a capsule) treatment chronic bronchitis, matched group adopts the disclosed Chinese and western medicinal composition of CN1165021A (dosage form is a capsule):
(1), clinical data:
1. physical data: this group patient is a nineteen ninety-five December～be in hospital in July, 1999 or 228 routine chronic bronchitis people of outpatient service diagnosis and treatment, get rid of other respiratory tract disease, be divided into treatment group (medicament capsule of the present invention) and matched group (the disclosed medicament capsule of CN1165021A).163 examples are organized in treatment, wherein male 102 examples, women 61 examples; The oldest 80 years old, reckling 19 years old, 48.4 years old mean age; The elder of the course of disease 32 years, the shortest person 3 years, average course of disease 16.3 years; Simple type 113 examples, the type of panting 50 examples.Matched group 65 examples, wherein male 40 examples, women 25 examples; The oldest person 78 years old, reckling 20 years old, 49.2 years old mean age; The elder of the course of disease 31 years, the shortest person 4 years, average course of disease 17.2 years; Simple type 47 examples, the type of panting 18 examples.
2. diagnostic criteria: draft (Chen Guiting, Yang Sishu, Beijing: Chinese medicine Science Press, 1991 according to " practical combination of Chinese and Western medicine diagnoses and treatment ", 250), clinically with cough, to cough up phlegm be cardinal symptom or with panting, annual morbidity continues 3 months, and continuous more than 2 years.Eliminating has cough, the other diseases of the symptom of coughing up phlegm (as pulmonary tuberculosis, pneumoconiosis, pulmonary abscess, cardiac insufficiency etc.) person.
3. state of an illness criterion: draft cough according to " practical combination of Chinese and Western medicine diagnoses and treatment ": the cough on daytime does not influence orthobiosis and work (+); Cough round the clock influences orthobiosis, work and sleep (+++); (++) falls between.Expectoration 10～50ml (+); 51～100ml (++); The above person of 100ml (+++).Pant: accidental, do not influence sleep (+); Can not put down for sleeping inly, influence activity (+++); Between the two (++).Wheezing sound: idol is heard, or (+) occur in cough and the dark fast back of breathing; Be dispersed in fixing (++); Be abound with (+++).
4. the traditional Chinese medical science is distinguished the disease standard: draft according to " practical combination of Chinese and Western medicine diagnoses and treatment ", 1. picture of the tongue: body of the tongue is light red or light, the white or whiten of tongue fur; 2. pulse condition: heavy thin or empty, or slow; 3. cough: the clear rare color of expectorant is white; 4. pale complexion: lose heart, lack of appetite, tired; 5. fear of cold or vest are cold; 6. the heavy summer in winter light, suffer from cold and promptly cough.During diagnosis 1., 3. indispensable, all the other 4 possess 2 promptly diagnosable.This data 209 examples all meet above-mentioned Chinese and western medicine diagnostic criteria.
(2), Therapeutic Method
1. treatment group: medicament capsule of the present invention, oral one time 3,3 times on the one, taking medicine after meal, 28 days courses of treatment.
2. matched group: oral control drug capsule, one time 3,3 times on the one, taking medicine after meal, 28 days courses of treatment.
(3), observation of curative effect
1. efficacy assessment standard (drafting): 1. clinic control according to " standard that chronic bronchitis in 1979 whole nation specialized conference is formulated ": symptom and pulmonary's wheezing sound are not enough slight person, or cough, expectorant, asthma shape takes a turn for the better more than ninety percent.2. produce effects: cough, expectorant, the asthma shape takes a turn for the better more than sixty percent or pulmonary's wheezing sound is clearly better; 3. take a turn for the better: symptom and pulmonary's wheezing sound do not have change, or three one-tenth persons of improvement less than; 4. invalid: cough, expectorant, breathe heavily and four of pulmonary's wheezing sounds invalid, and have more than one in four and increase the weight of.
2. recurrence standard: behind the clinical cure, cough, expectorant, breathe heavily and pulmonary's wheezing sound occurs once again, its degree was at least more than slight lasting February.
(4), two groups of curative effects of therapeutic outcome relatively see Table 3
Table 3 liang group clinical efficacy synopsis
| Group | n | Clinic control | Produce effects | Take a turn for the better | Invalid | Obvious effective rate | Total effective rate | |||||
| The example number | (％) | The example number | (％) | The example number | (％) | The example number | (％) | ????％ | The example number | (％) | ||
| Treatment group matched group | 163 ?65 | ?58 ?16 | ?35.6 ?24.6 | ?65 ?19 | 39.9 29.2 | ?35 ?20 | 21.4 30.8 | ????5 ????10 | ????3.2 ????15.4 | ????75.5* ????53.8 | ????158 ????55 | 96.8* 84.6 |
* compare P＜0.05 with matched group
As shown in Table 3, treatment group and matched group relatively treating chronic bronchitis clinical efficacy difference significance (P＜0.05) for two groups, and the curative curative effect obviously are better than contrasting medicine.
Usage and consumption: an oral 2-3 grain, 3 times on the one, taking medicine after meal.
Abovely the present invention is had been described in detail with reference to embodiment; clearly; for a person skilled in the art, do not exceed the protection domain that limits by the appended claims book, can the pharmaceutical composition of treatment asthma of the present invention, tracheitis be further improved.
Claims (5)
1, a kind of pharmaceutical composition for the treatment of asthma, tracheitis is characterized in that it is the medicament of being made by the following weight proportion raw material:
Herba Ephedrae 4--8 weight portion, Ramulus Cinnamomi 7--11 weight portion, Semen Armeniacae Amarum 9--15 weight portion, Radix Glycyrrhizae 4--8, Bulbus Fritillariae Uninbracteatae 4--8 weight portion, Radix Ginseng 7-11 weight portion, Fu Ling 12--18 weight portion, Rhizoma Atractylodis Macrocephalae 8--15 weight portion, Fructus Schisandrae Chinensis 9--15 weight portion, Fructus Psoraleae 9--15 weight portion, Gecko 4--8 weight portion, Cordyceps 4--8 weight portion.
2, the described pharmaceutical composition of claim 1 is characterized in that it is the medicament of being made by the following weight proportion raw material:
Herba Ephedrae 5--7 weight portion, Ramulus Cinnamomi 8--10 weight portion, Semen Armeniacae Amarum 10.5--14 weight portion, Radix Glycyrrhizae 5--7 weight portion, Bulbus Fritillariae Uninbracteatae 5--7 weight portion, Radix Ginseng 8-10 weight portion, Fu Ling 13.5--16.5 weight portion, Rhizoma Atractylodis Macrocephalae 10.5--13.5 weight portion, Fructus Schisandrae Chinensis 10--13 weight portion, Fructus Psoraleae 11.5--13.5 weight portion, Gecko 5--7 weight portion, Cordyceps 5--7 weight portion.
3, the described pharmaceutical composition of claim 1 is characterized in that it is the medicament of being made by the following weight proportion raw material:
Herba Ephedrae 6 weight portions, Ramulus Cinnamomi 9 weight portions, Semen Armeniacae Amarum 12 weight portions, Radix Glycyrrhizae 6 weight portions, Bulbus Fritillariae Uninbracteatae 6 weight portions, Radix Ginseng 9 weight portions, Fu Ling 15 weight portions, the Rhizoma Atractylodis Macrocephalae 12 weight portions, Fructus Schisandrae Chinensis 12 weight portions, Fructus Psoraleae 12 weight portions, Gecko 6 weight portions, Cordyceps 6 weight portions.
4, the medicine of claim 1,2 or 3 described treatment asthma, tracheitis is characterized in that said medicament is a said dosage form on any pharmaceutics.
5, the described treatment asthma of claim 4, bronchitic medicine is characterized in that said medicament is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99123941 CN1296847A (en) | 1999-11-18 | 1999-11-18 | Medicinal composition for treating asthma and tracheitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99123941 CN1296847A (en) | 1999-11-18 | 1999-11-18 | Medicinal composition for treating asthma and tracheitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1296847A true CN1296847A (en) | 2001-05-30 |
Family
ID=5283065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99123941 Pending CN1296847A (en) | 1999-11-18 | 1999-11-18 | Medicinal composition for treating asthma and tracheitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296847A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396544B (en) * | 2007-09-26 | 2011-08-17 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition capable of ventilating the lung and relieving asthma and preparation method thereof |
| CN103721026A (en) * | 2013-12-30 | 2014-04-16 | 李安海 | Traditional Chinese medicine for treating bronchial asthma and preparation method thereof |
| CN107496578A (en) * | 2017-08-15 | 2017-12-22 | 贵州盘州阿卡迪亚医疗管理有限公司 | Treat Chinese medicine composition of chronic cough and asthma and preparation method and application |
-
1999
- 1999-11-18 CN CN 99123941 patent/CN1296847A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396544B (en) * | 2007-09-26 | 2011-08-17 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition capable of ventilating the lung and relieving asthma and preparation method thereof |
| CN103721026A (en) * | 2013-12-30 | 2014-04-16 | 李安海 | Traditional Chinese medicine for treating bronchial asthma and preparation method thereof |
| CN107496578A (en) * | 2017-08-15 | 2017-12-22 | 贵州盘州阿卡迪亚医疗管理有限公司 | Treat Chinese medicine composition of chronic cough and asthma and preparation method and application |
| CN107496578B (en) * | 2017-08-15 | 2020-11-13 | 贵州盘州信捷医疗管理有限公司 | Traditional Chinese medicine composition for treating chronic cough and asthma and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105233231A (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN100389802C (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN109718286A (en) | For treating external application type Traditional Chinese medicine composition patch, preparation and its application of fever | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN1054528C (en) | Already prepared traditional Chinese medicine for treating psoriasis named "kangyinlin" | |
| CN108785583B (en) | Cough-relieving pharmaceutical composition and preparation method and application thereof | |
| CN1296847A (en) | Medicinal composition for treating asthma and tracheitis | |
| CN1062473C (en) | Medicinal composition for treating chronic obstructive disease of lung and its preparing process | |
| CN1328847A (en) | Chinese medicine preparation for curing pneumoconiosis | |
| CN1686492A (en) | Antibicrobial anti inflammatory capsule and its preparation method | |
| CN103520550B (en) | Traditional Chinese medicine for treating external cold internal rheum type chronic bronchitis and preparation method thereof | |
| CN112237604A (en) | Traditional Chinese medicine incense for reducing epidemic infection and preparation process thereof | |
| CN105381388A (en) | Traditional Chinese medicine composition for treating stomach discomfort and preparing method thereof | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN115006466B (en) | Traditional Chinese medicine preparation for treating eczema with damp-heat and yang deficiency and preparation method thereof | |
| CN1067563C (en) | Medicinal composition for treating acute cough and asthma and its preparing process | |
| CN115531503B (en) | External traditional Chinese medicine composition for novel coronavirus pneumonia recovery period, acupoint patch, preparation method and application | |
| CN1059107C (en) | Medicinal composition for treating chronic obstructive disease of lung and its preparing process | |
| CN114832065B (en) | Traditional Chinese medicine composition and preparation for treating acne and preparation method thereof | |
| CN114732887B (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN1267537A (en) | Medicinal composition for asthma and trachitis and its preparation | |
| CN113288969A (en) | Medicine for treating bronchitis and preparation method thereof | |
| CN103599341B (en) | A kind of pharmaceutical composition for the treatment of cough with asthma | |
| CN104707124A (en) | Traditional Chinese medicine preparation for treating chronic endometritis | |
| CN114558066A (en) | Pharmaceutical composition for treating cough variant asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiang Shibing Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiang Shibing Document name: Notice of publication of application for patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiang Shibing Document name: Notification before expiration of term |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiang Shibing Document name: Deemed as a notice of withdrawal |